X4 Pharmaceuticals's three largest insider shareholders as of May 30, 2026 are Paula Ragan (President And Ceo, 3.34Mn shares), Mary Dibiase (Chief Operating Officer, 1.14Mn shares), Christophe Arbet-Engels (Chief Medical Officer, 864.21K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Michael S Wyzga | - | 5,555 | 0 | 10 Jun, 2025 |
| David W J Mcgirr | - | 4,722 | 0 | 10 Jun, 2025 |
| David Kirske | Chief Financial Officer | 193,254 | 0 | 14 Aug, 2025 |
| Adam R Craig | Executive Chairman | 376,087 | 0 | 27 Oct, 2025 |
| Alison Frances Lawton | - | 96,667 | 0 | 11 Jun, 2024 |
| William Aliski | - | 96,667 | 0 | 11 Jun, 2024 |
| Gary Bridger | - | 4,722 | 0 | 10 Jun, 2025 |
| Mark Baldry | Chief Commercial Officer | 25,337 | 0 | 03 Jun, 2025 |
| Murray Stewart | Interim Chief Medical Officer | 7,883 | 0 | 10 Jun, 2025 |
| Adam S. Mostafa | Chief Financial Officer | 850,000 | 0 | 14 Feb, 2025 |
| Derek M Meisner | Chief Legal Officer | 145,155 | 0 | 19 Aug, 2022 |
| Paula Ragan | President And Ceo | 3,337,386 | 0 | 14 Feb, 2025 |
| Diego Cadavid | Chief Medical Officer | 104,107 | 0 | 01 Mar, 2022 |
| Christophe Arbet-Engels | Chief Medical Officer | 864,207 | 0 | 14 Feb, 2025 |
| Arthur Taveras | Chief Scientific Officer | 388,026 | 0 | 08 Oct, 2024 |
| Mary Dibiase | Chief Operating Officer | 1,140,980 | 0 | 14 Feb, 2025 |
| Craecker Francoise De | - | 4,722 | 0 | 10 Jun, 2025 |
| Keith Woods | - | 6,000 | 0 | 10 Jun, 2025 |
| Natasha Fay Thoren | Chief Legal Officer | 9,462 | 0 | 03 Jul, 2025 |
| John Volpone | President | 289,881 | 0 | 14 Aug, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Jan, 2026 | Gary Bridger | Stock Option (right to buy) | A | 110,000 | $0.00 | 0 | D | A |
| 01 Jan, 2026 | Michael S Wyzga | Stock Option (right to buy) | A | 110,000 | $0.00 | 0 | D | A |
| 01 Jan, 2026 | Craecker Francoise De | Stock Option (right to buy) | A | 110,000 | $0.00 | 0 | D | A |
| 01 Jan, 2026 | Craecker Francoise De | Stock Option (right to buy) | A | 110,000 | $0.00 | 0 | D | A |
| 01 Jan, 2026 | Murray Stewart | Stock Option (right to buy) | A | 110,000 | $0.00 | 0 | D | A |
| 29 Oct, 2025 | John Volpone | Stock Option (right to buy) | A | 2,329,154 | $0.00 | 2,329,154 | D | A |
| 29 Oct, 2025 | Adam R Craig | Stock Option (right to buy) | A | 2,329,154 | $0.00 | 2,329,154 | D | A |
| 29 Oct, 2025 | David Kirske | Stock Option (right to buy) | A | 1,552,769 | $0.00 | 1,552,769 | D | A |
| 23 Oct, 2025 | Adam R Craig | Common Stock | A | 86,206 | $2.90 | 376,087 | D | P |
| 14 Aug, 2025 | John Volpone | Common Stock | A | 289,881 | $0.00 | 289,881 | D | A |
| 14 Aug, 2025 | Adam R Craig | Common Stock | A | 289,881 | $0.00 | 289,881 | D | A |
| 14 Aug, 2025 | David Kirske | Common Stock | A | 193,254 | $0.00 | 193,254 | D | A |
| 12 Aug, 2025 | Adam R Craig | Stock Option (right to buy) | A | 1,609,873 | $0.00 | 1,609,873 | D | A |
| 12 Aug, 2025 | John Volpone | Stock Option (right to buy) | A | 1,609,873 | $0.00 | 1,609,873 | D | A |
| 12 Aug, 2025 | David Kirske | Stock Option (right to buy) | A | 1,073,249 | $0.00 | 1,073,249 | D | A |
| 14 Aug, 2025 | John Volpone | Stock Option (right to buy) | A | 529,201 | $0.00 | 529,201 | D | A |
| 14 Aug, 2025 | Adam R Craig | Stock Option (right to buy) | A | 529,201 | $0.00 | 529,201 | D | A |
| 14 Aug, 2025 | David Kirske | Stock Option (right to buy) | A | 352,800 | $0.00 | 352,800 | D | A |
| 20 May, 2025 | Natasha Fay Thoren | Common Stock | A | 3,333 | $0.00 | 9,462 | D | A |
| 09 Jun, 2025 | Michael S Wyzga | Common Stock | A | 1,500 | $0.00 | 5,555 | D | A |